This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

The Effects on Aqueous Dynamics of PhXA41, a New Prostaglandin F2 Analogue, After Topical Application in Normal and Ocular Hypertensive Human Eyes

Niloofar Ziai, MD; Joseph W. Dolan, MD; Richard D. Kacere, MD; Richard F. Brubaker, MD

Arch Ophthalmol. 1993;111(10):1351-1358.

Abstract
Objective
To study the effects of a topically applied prostaglandin F₂ analogue, PhXA41 (Latanoprost; 13,14-dihydro-17-phenyl-18,19,20-trinor-prostaglandin F₂-isopropyl ester), on aqueous dynamics in the human eye.

Design
A randomized, double-masked study was carried out on 20 normal and 20 ocular hypertensive humans. One eye of each subject was treated with 0.006% PhXA41, while the contralateral eye received placebo twice daily for 5 days.

Main Outcome
Compared with placebo, PhXA41 reduced intraocular pressure in both groups by approximately 20%.

Results
Tonographic facility of outflow was increased 24% in the normal group and 30% in the ocular hypertensive group; no changes were observed in the rates of aqueous humor flow in either group. The changes in tonographic facility were insufficient to fully explain the ocular hypotensive effect of the drug, suggesting that PhXA41 enhances outflow via the uveoscleral pathway. The suitability of fluorophotometry as a measure of flow was confirmed by three methods of comparing blood-aqueous barrier permeability: polarization of cameral fluorescence, intensity of backscattered light from the anterior chamber (flare), and cameral fluorescence after oral administration of fluorescein sodium. All of these measured parameters were normal, suggesting that this compound has no clinically significant effects on the blood-aqueous barrier or on the accuracy of fluorophotometry. PhXA41 was well tolerated in both groups. Only four of 40 subjects reported a transient foreign-body sensation, and only one of 40 subjects was observed to have greater than moderate conjunctival hyperemia. Most subjects had no symptoms and no measurable hyperemia.

Conclusions
These results suggest that PhXA41 is a potentially useful ocular hypotensive agent that enhances the egress of aqueous humor via both major outflow pathways. The relative lack of ocular side effects in this study further suggests that this agent has promise for the treatment of chronic glaucoma.

Author Affiliations
From the Department of Ophthalmology, Mayo Clinic and Mayo Foundation (Drs Ziai and Brubaker), and the Mayo Medical School (Drs Dolan and Kacere), Rochester, Minn.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Efficacy and Safety of Gold Micro Shunt Implantation to the Supraciliary Space in Patients With Glaucoma: A Pilot Study
Melamed et al.
Arch Ophthalmol 2009;127:264-269.
ABSTRACT | FULL TEXT  

Use of ocular hypotensive prostaglandin analogues in patients with uveitis: does their use increase anterior uveitis and cystoid macular oedema?
Chang et al.
Br J Ophthalmol 2008;92:916-921.
ABSTRACT | FULL TEXT  

Effect of 15-Keto Latanoprost on Intraocular Pressure and Aqueous Humor Dynamics in Monkey Eyes
Wang et al.
IOVS 2007;48:4143-4147.
ABSTRACT | FULL TEXT  

Evidence for the Involvement of Cannabinoid CB1 Receptors in the Bimatoprost-Induced Contractions on the Human Isolated Ciliary Muscle
Romano and Lograno
IOVS 2007;48:3677-3682.
ABSTRACT | FULL TEXT  

Short-Term Effects of Latanoprost on Anterior Chamber Depth in Patients with Glaucoma or Ocular Hypertension
Gutierrez-Ortiz et al.
IOVS 2006;47:4856-4859.
ABSTRACT | FULL TEXT  

Can NSAIDs and prostaglandin analogues be combined?
Alm
Br J Ophthalmol 2006;90:259-260.
FULL TEXT  

Prostaglandin Analogues and Mouse Intraocular Pressure: Effects of Tafluprost, Latanoprost, Travoprost, and Unoprostone, Considering 24-Hour Variation
Ota et al.
IOVS 2005;46:2006-2011.
ABSTRACT | FULL TEXT  

Effects of the combination of bimatoprost and latanoprost on intraocular pressure in primary open angle glaucoma: a randomised clinical trial
Doi et al.
Br J Ophthalmol 2005;89:547-549.
ABSTRACT | FULL TEXT  

Increase in Outflow Facility With Unoprostone Treatment in Ocular Hypertensive Patients
Toris et al.
Arch Ophthalmol 2004;122:1782-1787.
ABSTRACT | FULL TEXT  

Additivity of Bimatoprost or Travoprost to Latanoprost in Glaucomatous Monkey Eyes
Gagliuso et al.
Arch Ophthalmol 2004;122:1342-1347.
ABSTRACT | FULL TEXT  

Effect of Latanoprost on Outflow Facility in the Mouse
Crowston et al.
IOVS 2004;45:2240-2245.
ABSTRACT | FULL TEXT  

A comparison of the fixed combination of latanoprost and timolol with the unfixed combination of brimonidine and timolol in patients with elevated intraocular pressure. A six month, evaluator masked, multicentre study in Europe
Garcia-Sanchez et al.
Br J Ophthalmol 2004;88:877-883.
ABSTRACT | FULL TEXT  

Tonometric Changes of Latanoprost-Induced Intraocular Pressure Reduction after Photorefractive Keratectomy
Tamburrelli et al.
IOVS 2004;45:846-850.
ABSTRACT | FULL TEXT  

Paradoxical Intraocular Pressure Elevation After Combined Therapy With Latanoprost and Bimatoprost
Herndon et al.
Arch Ophthalmol 2002;120:847-849.
FULL TEXT  

Additive effect of unoprostone and latanoprost in patients with elevated intraocular pressure
Aung et al.
Br J Ophthalmol 2002;86:75-79.
ABSTRACT | FULL TEXT  

From PGF2{{alpha}}-Isopropyl Ester to Latanoprost: A Review of the Development of Xalatan The Proctor Lecture
Stjernschantz
IOVS 2001;42:1134-1145.
FULL TEXT  

Comparison of the intraocular pressure lowering effect of latanoprost and a fixed combination of timolol-pilocarpine eye drops in patients insufficiently controlled with beta adrenergic antagonists
Nordmann et al.
Br J Ophthalmol 2000;84:181-185.
ABSTRACT | FULL TEXT  

Increase of Intraocular Pressure After Topical Administration of Prostaglandin Analogs
Ness and Funk
Arch Ophthalmol 1999;117:1646-1647.
FULL TEXT  

Effect of Latanoprost on Regional Blood Flow and Capillary Permeability in the Monkey Eye
Stjernschantz et al.
Arch Ophthalmol 1999;117:1363-1367.
ABSTRACT | FULL TEXT  

Topical Prostaglandin F2{alpha} Treatment Reduces Collagen Types I, III, and IV in the Monkey Uveoscleral Outflow Pathway
Sagara et al.
Arch Ophthalmol 1999;117:794-801.
ABSTRACT | FULL TEXT  

Comparison of the Early Effects of Brimonidine and Apraclonidine as Topical Ocular Hypotensive Agents
Maus et al.
Arch Ophthalmol 1999;117:586-591.
ABSTRACT | FULL TEXT  

Latanoprost Accelerates Disruption of the Blood-Aqueous Barrier and the Incidence of Angiographic Cystoid Macular Edema in Early Postoperative Pseudophakias
Miyake et al.
Arch Ophthalmol 1999;117:34-40.
ABSTRACT | FULL TEXT  

Effects of latanoprost and dipivefrin, alone or combined, on intraocular pressure and on blood-aqueous barrier permeability
Widengård et al.
Br J Ophthalmol 1998;82:404-406.
ABSTRACT | FULL TEXT  

Effect of latanoprost on intraocular pressure in patients with glaucoma on maximal tolerated medical treatment
AZUARA-BLANCO et al.
Br J Ophthalmol 1997;81:1115b-1115.
FULL TEXT  

Functional Characterization of the Ocular Prostaglandin F2alpha (PGF2alpha ) Receptor. ACTIVATION BY THE ISOPROSTANE, 12-iso-PGF2alpha
Kunapuli et al.
J. Biol. Chem. 1997;272:27147-27154.
ABSTRACT | FULL TEXT  

A double masked comparison of the intraocular pressure reducing effect of latanoprost 0.005% and 0.001% administered once daily in open angle glaucoma and ocular hypertension
Fristrom and Nilsson
Br J Ophthalmol 1997;81:867-870.
ABSTRACT | FULL TEXT  

Latanoprost and Physostigmine Have Mostly Additive Ocular Hypotensive Effects in Human Eyes
Linden and Alm
Arch Ophthalmol 1997;115:857-861.
ABSTRACT  

Effects on IOP restoration and blood-aqueous barrier after long term treatment with latanoprost in open angle glaucoma and ocular hypertension
Linden et al.
Br J Ophthalmol 1997;81:370-372.
ABSTRACT | FULL TEXT  

A Comparison of Latanoprost and Timolol in Primary Open-angle Glaucoma and Ocular Hypertension: A 12-Week Study
Mishima et al.
Arch Ophthalmol 1996;114:929-932.
ABSTRACT  

Will Latanoprost Be the 'Wonder' Drug of the '90s for the Treatment of Glaucoma?
Higginbotham
Arch Ophthalmol 1996;114:998-999.
ABSTRACT